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A B S T R A C T
Background
Loperamide is widely used in adults for acute diarrhea. However, its use in children has been
discouraged by the World Health Organization and the American Academy of Pediatrics owing
to concerns over safety and efficacy in young children.
Methods and Findings
To assess the efficacy and adverse effects of loperamide compared with placebo for acute
diarrhea in children, we reviewed Medline, EMBase, the Cochrane Central Register of Controlled
Trials, and bibliographies of known clinical trials and of review articles, and we also interviewed
key investigators in the field. We undertook a systematic review and meta-analysis of
randomized controlled trials of children younger than 12 y of age with acute diarrhea,
comparing loperamide with placebo. Included trials reported data on diarrhea duration or
severity, or provided data on adverse effects. Compared with patients who received placebo,
patients allocated to loperamide were less likely to continue to have diarrhea at 24 h
(prevalence ratio 0.66, 95% confidence interval [CI]: 0.57 to 0.78), had a shorter duration of
diarrhea by 0.8 d (95% CI: 0.7 to 0.9 d), and had a lower count of stools at 24 h (0.84, 95% CI:
0.77 to 0.92). Results were similar when random-effects summaries were estimated. Serious
adverse events, defined as ileus, lethargy, or death, were reported in eight out of 927 children
allocated to loperamide (0.9%, 95% CI: 0.4% to 1.7%). Serious adverse events were not reported
in any of the 764 children allocated to placebo (0%, 95% CI: 0% to 0.5%). Among the children
allocated to loperamide, serious adverse events were reported only among children younger
than 3 y.
Conclusions
In children who are younger than 3 y, malnourished, moderately or severely dehydrated,
systemically ill, or have bloody diarrhea, adverse events outweigh benefits even at doses 0.25
mg/kg/d. In children who are older than 3 y with no/minimal dehydration, loperamide may be
a useful adjunct to oral rehydration and early refeeding.
The Editors’ Summary of this article follows the references.
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Introduction
Worldwide, children younger than 5 y of age have
approximately three cases of diarrhea annually and 1.6–2.5
million children younger than 5 y die each year from
diarrhea, as estimated from studies published between 1992
and 2000 [1]. The national health-care cost for diarrhea-
associated disease in the United States was estimated to be
US$1.55 billion in 2002 [2]. In a 1997 survey, an estimated
34% of persons with a diarrheal illness in the United States
reported taking anti-diarrheal medications [3]. Some review
papers on the treatment of acute diarrhea in adults suggest
loperamide as a first-line agent [4,5]. Although loperamide is
widely used in adults, the World Health Organization and the
American Academy of Pediatrics are concerned about its use
in young children because of concerns over its efficacy and
safety [6,7]. In the United States, loperamide is approved by
the Food and Drug Administration for use in children older
than 2 y of age.
We conducted a systematic review and meta-analysis of
randomized controlled trials to estimate whether loperamide
use influenced the duration of diarrhea or the number of
diarrheal stools in children younger than 12 y of age with
acute diarrhea (see Text S1 for the QUOROM checklist). We
also searched the literature for information about adverse
effects of loperamide.
Methods
Data Sources
First, we searched the following databases: Medline (1966–
2006 ; h t tp : / /www.ncb i .n lm .n ih . gov / en trez /query .
fcgi?DB¼pubmed), EMBase (1988–2006; http://www.embase.
com), and the Cochrane Central Register of Controlled Trials
(http : / /www.mrw. intersc ience .wi ley .com/cochrane /
cochrane_clcentral_articles_fs.html, with the search car-
ried out on 24 April 2006) using the search terms ‘‘diarrhea/’’,
‘‘diarr$(tw)’’, ‘‘diarrhea(tw)’’, and ‘‘loperamide/’’ or ‘‘imodi-
um’’ [8]. In the Medline and EMBase databases, randomized
studies were identified by limiting our studies to ‘‘randomized
controlled trial’’, ‘‘multicenter study’’, ‘‘controlled clinical
trial’’, or ‘‘clinical trial’’. Second, we searched bibliographies
of known clinical trials and of review articles for other
eligible publications. Third, we contacted major health
organizations that focus on diarrhea prevention and treat-
ment, key investigators in the field, and major pharmaceutical
companies that manufacture loperamide (McNeil Consumer
Healthcare, http://www.imodium.com) to ask for details of
other known clinical trials. Primary authors were contacted
to obtain additional information if necessary. Conference
proceedings were not searched. Publications were included in
all languages.
Study Selection
We evaluated each trial for inclusion in the review on the
basis of four criteria: study design (randomized controlled
trial), study population (children younger than 12 y of age
with acute diarrhea), intervention (loperamide versus con-
trol), and availability of outcome data on diarrhea duration
or severity. Studies fulfilling all four criteria were included.
Studies of the combination of loperamide and another drug,
such as an antibiotic, were not included.
Outcome Measures
Our primary outcomes of interest were the characteristics
of the clinical course of diarrhea and the incidence of adverse
events. Measures of diarrhea intensity included duration (in
days), frequency (number of stools per day), and stool volume.
Serious adverse events were considered to be ileus, lethargy,
or death.
Methodological Quality of Studies
We recorded four aspects of study design: allocation
concealment, generation of allocation sequence, blinding,
and inclusion of all randomized participants. Allocation
concealment, generation of allocation sequence, and blinding
of the treatment assessor were categorized as adequate, not
adequate, or unclear. Allocation concealment was catego-
rized as adequate (patients and investigators enrolling
patients cannot foresee assignment), inadequate (authors
did not report an allocation-concealment approach or
reported an approach that could not be considered
adequate), or unclear (allocation concealment was stated,
but the method used was not described). Generation of
allocation sequence was categorized as adequate (sequences
are suitable to prevent selection bias, and method used is
described), inadequate (sequences could be related to
prognosis), or unclear (generation of allocation sequence
was stated, but method was not described). Blinding was
categorized as double-blind (neither patient nor care
provider/assessor knows which treatment is given), single-
blind (patient or care provider/assessor is aware of treatment
given, and open (all parties are aware of treatment). Inclusion
of all randomized participants was categorized as adequate if
more than 90% of randomized patients were included in the
intention-to-treat analysis, or inadequate if it was unclear or
if fewer than 90% of patients were included in the intention-
to-treat analysis. Studies were not excluded on the basis of
methodological quality of trials, but this information was
used in the sensitivity analysis.
Data Abstraction
Data were extracted independently by two authors (STL
and DCG) and any disagreements were resolved by consensus.
Study Characteristics
Descriptive data for each trial included details of partic-
ipants (i.e., age), country of trial, stool pathogens, details of
intervention (including study medication and dose), and
definition of outcomes. Our assessment of clinical hetero-
geneity was focused on loperamide dose and definition of
diarrhea resolution across the trials.
Statistical Methods
Publications with common outcome measures were in-
cluded in a meta-analysis. We summarized risk ratios and
mean differences across studies primarily using the fixed-
effects method: the Mantel-Haenszel method for dichoto-
mous outcomes, or the inverse variance method for contin-
uous outcomes [9–11]. Data on diarrhea counts in the first 24
h were summarized using the log of the count ratio from each
study and inverse variance weights [12,13]. We used the
random-effects method of DerSimonian and Laird to see if
this changed the results [9–11]. We performed tests for
heterogeneity using the Mantel-Haenszel or inverse variance
methods [9–11].
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Adverse outcomes were rare; to estimate the 95%
confidence intervals (CIs) for the cumulative risk of an
adverse event in each trial arm, we used exact (Clopper-
Pearson) binomial methods [9,14,15]. To obtain pooled risk
difference estimates, we used the Mantel-Haenszel method
[9–11].
Subanalyses were planned a priori to determine whether
dose of loperamide, definition of diarrhea resolution,
location of subject population (outpatient or inpatient),
methodological quality, or infectious agent (bacteria or virus
isolated from stools) modified the effect of loperamide on
diarrhea or explained any heterogeneity seen. Preplanned
subanalyses were performed only if the characteristic of
interest was reported in three or more studies.
All analyses were performed using Stata 8.0 (Stata, College
Station, Texas, United States) [9,10,12].
Results
Study Selection
The initial search for studies involving loperamide treat-
ment of infectious diarrhea yielded 345 articles. Review of the
abstracts and exclusion of irrelevant and duplicate articles
yielded 91 articles (Figure 1). Key researchers in the field did
not suggest any additional trials. Of the 91 articles examined,
we excluded 34 studies with no control group, 16 studies
where children younger than 12 y of age were not included,
one study where we were unable to determine the number of
children younger than 12 y of age, and 24 studies that did not
otherwise meet inclusion criteria, leaving 16 studies that met
the four inclusion criteria (Figure 1) [16–31]. We excluded
one study because only subanalysis results were presented
[29]. An additional two studies were not included in the
systematic review because neither adverse effects nor out-
come data that could be combined were available in either of
the studies [28,30].
Study Characteristics
The 13 included trials studied 1,788 children younger than
12 y: 975 children assigned to loperamide and 813 assigned to
placebo. Of the 13 studies, six studies used loperamide doses
0.25 mg/kg/d, four studies used doses .0.25 mg/kg/d, and
three studies used unclear maximum doses (Table 1).
Definitions of diarrhea resolution were not uniform across
studies (Table 1). While four out of 13 studies defined
diarrhea resolution as the time to the last unformed stool
[16,17,26,31], four studies defined diarrhea resolution as
change in stool consistency [22], ,15 g of stool/kg/d [24],
two or fewer liquid/soft stools/d [18], or return to normal
bowel habits [21], and five studies did not report their criteria
for diarrhea resolution [19,20,23,25,27].
Most of the patients were only mildly dehydrated, had a
non-bacterial cause of their diarrhea, and had diarrhea for
fewer than 3 d prior to enrolment in the studies (Table 1).
Most (11/13) studies reported that patients received oral
rehydration therapy in addition to the study medication
[17,19–21,23–27,31]. Only four studies specifically mentioned
that some of their patients received intravenous fluid
rehydration in addition to oral rehydration therapy [17–
19,27]; two studies did not report the hydration method used
[16,22]. Early refeeding was reported in four studies
[23,24,26,31]; restriction to only oral rehydration therapy in
the first 24 h was reported in two studies [20,25]; and six
studies did not report on feeding practices [16–19,22,27].
Methodological Quality of Trials
Generation of the allocation sequence was reported in only
six out of 13 studies (Table 2) [17,19,21,25,26,31]. Allocation
concealment was reported in seven studies [17,19–
21,25,26,31]. Although nine trials were double-blind
[16,17,19–21,25–27,31], four were open [18,22–24]. Most (11/
13) trials reported inclusion of more than 90% of all
randomized participants in their analysis [17–26,31]. Only
six studies met all four indicators of methodological quality
that we used [17,19,21,25,26,31], and of those, only four
provided outcome data that could be combined [17,19,21,31].
Quantitative Data Synthesis
Diarrhea continuing at 24 and 48 h. Data on diarrhea
continuing at 24 or 48 h were available in five studies [16–
18,24,31]. In the four studies reporting diarrhea at 24 h, the
prevalence of diarrhea among patients on loperamide was
less than among patients on placebo; prevalence ratio 0.66
(95% CI: 0.57 to 0.78) (Figure 2) [16–18,31]. When the meta-
analysis was restricted to the three studies that used the same
definition of diarrhea resolution, last unformed stool, the
prevalence of diarrhea among patients on loperamide was
less than among patients on placebo: prevalence ratio 0.66
(95% CI: 0.56 to 0.77) [16,17,31]. In the four studies reporting
diarrhea at 48 h among patients on loperamide, the
prevalence of diarrhea was less than among patients on
placebo: prevalence ratio 0.59 (95% CI: 0.45 to 0.78) (Figure 3)
[16,18,24,31].
Mean reduction in diarrhea duration. Data on diarrhea
duration were available for six studies [19–23,31]. Among
those on loperamide, compared with those assigned to
placebo, mean diarrhea duration was 0.8 d shorter, (95%
CI: 0.7 to 0.9 d) (Figure 4) [19–23,31]. Similar values for mean
reduction in diarrhea duration were estimated when re-
stricted to the five studies with a loperamide dose of 0.25
mg/kg/d (mean reduction in diarrhea duration 0.7 d, 95% CI:
0.6 to 0.8 d) [19–21,23,31].
Diarrhea frequency. Data on diarrhea counts in the first 24
h were available for four studies. Of these four studies, data
on diarrhea counts were available in 8-h intervals in three
studies [19,20,31] and in 24-h intervals in one study [21]. The
count of stools in the first 24 h was lower among patients on
loperamide compared with patients on placebo: count ratio
0.84 (95% CI: 0.77 to 0.92) (Figure 5) [19–21,31].
Adverse events. Data on adverse events were available from
12 studies [16–19,21–27,31]. Adverse events were reported in
94 out of 927 patients (10.1%, 95% CI: 8.3% to 12.3%)
allocated to loperamide and in 16 out of 764 patients (2.1%,
95% CI: 1.2% to 3.4%) allocated to placebo (risk difference
8.6% [95% CI: 6.4% to 10.9%]) (Table 3). Serious adverse
events, defined as ileus, lethargy, or death, occurred only
among children younger than 3 y of age [23,24,26]. We could
not estimate age-specific prevalence of adverse events since
counts of adverse events by age of child were not reported.
Serious adverse events were reported in eight out of 927
children allocated to loperamide (0.9%, 95% CI: 0.4% to
1.7%) but were not reported in any of the 764 children
allocated to placebo (0%, 95% CI: 0% to 0.5%): risk
difference 0.8% (95% CI: 0.1% to 1.8%). Lethargy was
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reported in four children younger than 3 y given 0.1 mg/kg/d
of loperamide [23]. The other serious adverse events were in
children younger than 3 y given 0.4–0.8 mg/kg/d of loper-
amide: ileus in a 4-mo-old infant [24], lethargy in two children
[26], and death from complications from Salmonella typhi
bacteremia in one child [26].
When the definition of serious adverse events was
expanded to include abdominal distension and sleepiness,
adverse events were recorded in 21 out of 927 children (2.3%,
95% CI: 1.4% to 3.4%) allocated to loperamide, and in four
out of 764 children (0.5%, 95% CI: 0.1% to 1.3%) allocated to
placebo (risk difference 1.8%, 95% CI: 0.6% to 3.1%).
Sleepiness was reported in seven patients, six of whom were
allocated to loperamide (0.25–0.8 mg/kg/day), with one child
allocated to placebo [24,31]. Of the children with sleepiness
recorded, four children allocated to loperamide 0.8 mg/kg/d
were younger than 3 mo of age [24]; the ages of the other
children with sleepiness were not reported. Abdominal
distension was reported in ten children under the age of 3
y, seven of whom were allocated to loperamide (0.24–0.8 mg/
kg/day), with three allocated to placebo [17,19,21,26].
Sensitivity analysis. We did not find any important changes
in our estimates when we restricted our analyses to studies
with loperamide at a dose of 0.25 mg/kg/d, studies on
outpatient populations, studies that fulfilled all four indica-
tors of methodological quality, studies that defined diarrhea
resolution, or studies with fewer than 25% of diarrhea cases
attributed to a bacterial pathogen (Table 3).
In addition, we did not find any changes in our overall
estimates when using the random-effects method (Table 4).
The smallest p-value for tests of homogeneity was 0.6 when
examining studies reporting diarrhea continuing at 24 or 48
h. Results from studies reporting differences in diarrhea
duration (expressed as a continuous variable) and diarrhea
frequency were more disparate; the p-values for tests of
homogeneity were ,0.01. All inferences continued to be
statistically significant with the random-effects method
except in sub-analyses (Table 3). Using the random-effects
method, the sub-analyses of the mean differences in diarrhea
duration were no longer statistically significant in meta-
analyses of studies of loperamide doses of 0.25 mg/kg/d, in
meta-analyses of studies that met all four indicators of
Figure 1. Summary of Meta-Analysis Flow
Some studies reported more than one outcome that could be summarized.
doi:10.1371/journal.pmed.0040098.g001
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methodological quality, or in meta-analyses of studies with
,25% diarrhea cases attributed to a bacterial pathogen
(Table 3). Using the random-effects method, the sub-analyses
of the mean differences of diarrhea count at 24 h were no
longer statistically significant in meta-analyses of studies that
met all four indicators of methodological quality (Table 4).
None of the factors examined in the sub-analyses could
account for study heterogeneity in the studies of diarrhea
duration or in the studies of diarrhea frequency; the p-values
of tests of homogeneity of these subgroups remained ,0.01.
We were unable to test whether a consistent definition of
diarrhea resolution could account for study heterogeneity
since no two of the studies of diarrhea duration or diarrhea
frequency defined diarrhea resolution in the same way.
Discussion
Loperamide appears to decrease diarrhea duration and
frequency in children when used as an adjunct to oral or
intravenous rehydration. Compared with patients given
placebo, patients who were randomized to loperamide were
34% less likely to have had diarrhea 24 after initiation of
therapy and 41% less likely to have had diarrhea 48 h after
initiation of therapy, had 0.8 fewer days of diarrhea, and had
a 16% reduction in diarrheal stools within the first 24 h of
treatment. Serious adverse events of death, ileus, or lethargy
were reported only in children younger than 3 y of age.
Our review should be evaluated with the following
limitations in mind. First, although our review drew from
an extensive search and was not limited by language,
conference proceedings were not searched. Therefore, it is
possible that additional information from conference pro-
ceedings that did not lead to a separate publication and that
were not noted by researchers in the field was missed.
Second, our meta-analysis was limited by a lack of
consistency in outcome measures, and this restricted our
ability to combine results across many trials. Although we
report the results of 13 studies, not all studies presented
outcomes that could be summarized. Stool volume could not
be summarized because only one study reported stool volume
with standard deviations. In addition, for many outcomes, no
results were reported. We were unable to examine whether
patients received intravenous fluid administration or hospi-
talization because these outcomes were so rarely reported.
Studies did not report whether loperamide prevented the
progression from acute to persistent diarrhea.
Third, we found evidence of heterogeneity for some
outcomes. We could not account for the observed hetero-
geneity in several subgroup analyses. Despite this hetero-
geneity, both fixed-effects and random-effects summaries
were consistent with beneficial effects of loperamide in the
overall estimates; the heterogeneity suggests the size of the
benefit varies by some other factor that we were not able to
identify.
Fourth, it is unclear how representative the children
recruited in the studies were compared with all children
worldwide with diarrhea. Although many studies included
children with mild dehydration, several studies did not report
hydration status [16,18,22,31] or specifically excluded chil-
dren with moderate [31] or severe dehydration [22,24,25,31]
(Table 1). No study reported nutritional status, and several
trials specifically excluded patients who were malnourished
[21,22,24,25]. While most studies included patients with
diarrhea from bacterial sources, several studies did not
report diarrhea etiology or specifically excluded patients
who had bloody diarrhea [24,25,31]. In addition, several
studies specifically excluded patients who were systemically ill
[21,22,24,25,31] or required antibiotics [21,24,31].
Finally, although serious adverse events were reported only
in children younger than 3 y of age, age-specific prevalence of
adverse events could not be calculated since studies reported
neither the count of adverse events by age of child nor the
Figure 2. Meta-Analysis of Prevalence of Diarrhea at 24 h among Those on Loperamide Compared with Controls
The x-axis uses the log scale. Random-effects prevalence ratio 0.66 (95% CI: 0.57 to 0.77). Test for heterogeneity, p¼ 0.914.
doi:10.1371/journal.pmed.0040098.g002
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count of total number of children in each age category. Our
reported prevalence of serious adverse events is an under-
estimate for children younger than 3 y and an overestimate
for children 3 y and older. In addition, randomized
controlled studies may not be the best way to determine the
incidence of rare adverse events. We provided both preva-
lence of serious adverse events (ileus, lethargy, and death) and
prevalence of an expanded version of serious adverse events
(including sleepiness and abdominal distension) because the
distinctions between sleepiness and lethargy, and between
abdominal distension and ileus, were not defined in the
studies. Before using loperamide, health-care providers and
parents should consider the potential benefit of whether
decreasing diarrhea duration by 1 d is worth the potential
risk of adverse events. Children who were malnourished, had
bloody diarrhea, were systemically ill, or were moderately/
Figure 3. Meta-Analysis of Prevalence of Diarrhea at 48 h among Those on Loperamide Compared with Controls
The x-axis uses the log scale. Random-effects prevalence ratio 0.58 (95% CI: 0.45 to 0.76). Test for heterogeneity, p¼ 0.864.
doi:10.1371/journal.pmed.0040098.g003
Figure 4. Diarrhea Duration
Reduction of diarrhea duration (days) in six included studies that reported mean reduction and variance using the fixed-effects method: 0.8-d reduction
in diarrhea (95% CI: 0.74 to 0.87 d). Box size is proportional to the inverse magnitude of the study variance. Random-effects reduction in diarrhea
duration: 0.56 d (95% CI: 0.16 to 0.95 d). Test for heterogeneity, p , 0.001.
doi:10.1371/journal.pmed.0040098.g004
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severely dehydrated were often excluded from these trials, so
loperamide should probably not be used in that population.
For children younger than 3 y, the risk of serious adverse
events probably outweighs the benefit of a potential 1-d
reduction in diarrhea duration. In addition, since loperamide
appears efficacious in doses as low as 0.1–0.25 mg/kg/d, the
lowest efficacious dose should be used to try to minimize the
risk of overdosing loperamide.
The results of our systematic review and meta-analysis are
consistent with a previous review on the efficacy and safety of
loperamide in adults [32]. In their 1990 review of the efficacy
and safety of loperamide for acute diarrhea in adults,
Ericsson et al. concluded that loperamide is effective and
safe for the treatment of diarrhea [32]. The authors reviewed
five studies of loperamide among persons of 8 y and older and
included studies that compared loperamide to another drug
(such as diphenoxylate or bismuth subsalicylate) [32]. To our
knowledge, our study is the first systematic review and meta-
analysis that focuses on the efficacy and safety of loperamide
in children.
Future studies of diarrhea might benefit from clear
definitions of minimum diarrhea severity for inclusion in a
trial, definitions of diarrhea resolution, and outcomes with
means and standard deviations which could be combined,
such as diarrhea duration, count of diarrheal stools at 24 h,
and number of patients with diarrhea resolution at 24 h. If
these definitions and outcomes were used consistently across
studies on acute diarrhea, studies would be more amenable to
being summarized with meta-analysis techniques. Logrank
tests (a comparison of the survival curves showing how
quickly diarrhea resolved in the loperamide and control
groups) [13] may be the most appropriate test in some
situations; however, including an outcome that could be
readily combined in meta-analysis may be helpful. In
addition, future studies of children might benefit from
presenting results and adverse event data by year of age
and treatment arm, as age may modify a child’s response to
treatment and risk of adverse events.
Oral rehydration therapy and early refeeding should
remain the focus of management of diarrhea. Loperamide
may be considered as an adjunct to oral rehydration therapy
and early refeeding. Since diarrhea is usually a self-limited
Table 3. Adverse Events: Prevalence of Adverse Events in Patients Treated with Loperamide or Placebo
Dose Adverse Events Adverse Events/Number of Patients (%) Risk Difference (95% CI)
Loperamide Control
 0.25 mg/kg/d
[19,21,23,27,31]
Ileus or lethargy 4/265 (1.5) 0/261 (0) 1.5% (0.6% to 0.4%)
Death 0/265 (0) 0/261 (0) 0% (1.7% to 1.7%)
Ileus/abdominal distension,
lethargy/sleepiness, or death
10/265 (3.8) 4/261 (1.5) 2.3% (0.5% to 5.1%)
All adverse events reported 28/265 (10.6) 13/261 (5.0) 5.6% (1.1% to 10.2%)
Possibly  0.25 mg/kg/d
[16,18,22]
Ileus, lethargy 0/303 (0) 0/261 (0) 0% (1.2% to 1.2%)
Death 0/303 (0) 0/261 (0) 0% (1.2% to 1.2%)
Ileus/abdominal distension,
lethargy/sleepiness, or death
0/303 (0) 0/261 (0) 0% (1.2% to 1.2%)
All adverse events reported 54/303 (17.8) 3/261 (1.1) 16.6% (12.1% to 21.0%)
.0.25 mg/kg/d
[17,24–26]
Ileus, lethargy, or death 4/359 (1.1) 0/242 (0) 1.1% (0.1% to 2.8%)
Ileus or lethargy 3/359 (0.8) 0/242 (0) 0.8% (0.1% to 2.6%)
Death 1/359 (0.3) 0/242 (0) 0.2% (1.3% to 1.7%)
Ileus/abdominal distension,
lethargy/sleepiness, or death
11/359 (3.1) 0/242 (0) 3.2% (1.0% to 5.5%)
All adverse events reported 12/359 (3.3) 0/242 (0) 3.6% (1.2% to 5.9%)
Total [16–19,21–27,31] Ileus, lethargy, or death 8/927 (0.9) 0/764 (0) 0.8% (0.1% to 1.8%)
Ileus or lethargy 7/927 (0.8) 0/764 (0) 0.8% (0.2% to 1.7%)
Death 1/927 (0.1) 0/764 (0) 0.1% (0.8% to 0.9%)
Ileus/abdominal distension;
lethargy/sleepiness, or death
21/927 (2.3) 4/764 (0.5) 1.8% (0.6% to 3.1%)
doi:10.1371/journal.pmed.0040098.t003
Figure 5. Meta-Analysis of Ratio of Mean Counts of Diarrheal stools at 24
h among Those on Loperamide Compared with Controls
The x-axis uses the log scale. Fixed-effects ratio of count of stools at 24 h:
0.84 (95% CI: 0.77 to 0.92). Random-effects ratio of count of stools at 24
h: 0.83 (95% CI: 0.69 to 1.00). Test for heterogeneity, p , 0.001
doi:10.1371/journal.pmed.0040098.g005
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disease in industrialized societies, physicians and families
should weigh the possibility of adverse events against a
modest improvement in diarrhea. In children who are
younger than 3 y, malnourished, moderately or severely
dehydrated, systemically ill, or have bloody diarrhea, adverse
events outweigh benefits even at doses 0.25 mg/kg/d. In
children who are older than 3 y with no/minimal dehydration,
loperamide may be a useful adjunct to oral rehydration and
early refeeding.
Supporting Information
Text S1. QUOROM Checklist
Found at doi:10.1371/journal.pmed.0040098.sd001 (33 KB DOC).
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4 0.66 (0.57 to 0.78) 0.66 (0.57 to 0.77) 0.91
Meta-analysis of prevalence
of diarrhea at 48 h
Overall [16,18,24,31] 4 0.59 (0.45 to 0.78) 0.58 (0.45 to 0.76) 0.86
,25% of diarrhea caused
by bacteria [16,18,31]
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Meta-analysis of ratio of mean counts
of diarrheal stools at 24 h
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Preplanned subanalyses were performed only if the characteristic of interest was reported in three or more studies.
doi:10.1371/journal.pmed.0040098.t004
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Editors’ Summary
Background. While diarrhea is often thought of as a mild, inconvenient
condition, it is estimated that, worldwide, 1.6–2.5 million children under
5 y old die each year from diarrhea, most of them in developing
countries. Dehydration is the key factor in the deaths of these children. In
richer countries, diarrhea is rarely deadly, but it has been calculated that,
in the United States, the annual national health-care cost associated with
the condition amounts to around US$1.5 billion. Some of the cost results
from the purchase of anti-diarrheal drugs. Loperamide is one of the most
widely used of these drugs. In most countries, it can be obtained without
a prescription. The use of loperamide is intended to reduce the
frequency of bowel movements, but taking it will not lead to
rehydration, nor will it kill the infectious organisms responsible for the
condition.
Why Was This Study Done? The World Health Organization and other
health authorities have concerns that loperamide may not be effective in
young children and that it may not be safe. In the United States, the
Food and Drug Administration approves its use for children older than 2
y of age. The researchers wanted to know whether loperamide could
play a useful part in treating diarrhea in children.
What Did the Researchers Do and Find? They did not do any new work
with children suffering from diarrhea. Instead, they searched the medical
literature for previously conducted trials involving the use of loperamide.
They used these previously conducted trials to estimate whether use of
loperamide influenced the duration of diarrhea or the number of
diarrheal stools in children under 12 y of age. They also used these trials
to examine adverse effects of loperamide. In total they found 13 studies
that met the criteria they had set for inclusion in their study. More than
900 children in these studies had been given loperamide for their
diarrhea; each trial also had a control group of children whose treatment
did not include loperamide. Most of the children in the studies had only
mild diarrhea. The researchers found that, compared with children in the
control groups, those treated with loperamide were less likely to
continue to have diarrhea 24 h later, had a shorter duration of diarrhea,
and had a lower count of diarrheal stools. However, eight of the children
given loperamide and none of the control group did have serious
adverse effects. All those who had serious adverse effects were less than
3 y of age.
What Do These Findings Mean? The researchers concluded that if a
child is less than 3 y of age, malnourished, moderately or severely
dehydrated, or has bloody diarrhea, the risk of adverse events from
loperamide treatment outweighs the benefits, even at low doses. In
other children, loperamide may be a useful part of treatment. However,
they advise that rehydrating the child (by giving fluids orally) and
progressively returning him or her to a normal diet should still be the
main focus in the treatment of childhood diarrhea.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040098.
 For advice on the treatment of diarrhea, visit the Web sites of
BestTreatments (produced by BMJ Publications) and of FamilyDoctor
(produced by the American Academy of Family Physicians)
 The World Health Organization has a Web page about diarrhea that
gives a global perspective on this major cause of childhood death
 UNICEF (the children’s organization of the United Nations) includes
diarrhea in its Facts for Life series, which aims to provide parents and
other caregivers with the information they need to save and improve
children’s lives; the messages contained in Facts for Life are based on
the latest scientific findings, but are presented in nontechnical
language
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